Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Eli Lilly Launch New Drug to Treat Acute Migraine in Adults

A new oral medication, REYVOW™ (lasmiditan) has been launched by Eli Lilly and Company for the treatment of acute migraine, with or without aura, in adults.

The drug, REYVOW is delivered orally via a tablet and is the first serotonin receptor agonist. It binds to (5-HT) 1F receptor with high affinity.

However, its exact mechanism is unknown yet.

The effectiveness of REYVOW was demonstrated in two randomized, double-blind, placebo-controlled trials.

In both the studies, the percentage of patients whose pain had resolved was significantly greater for those taking the medication rather than the placebo.

The treatment-emergent adverse events in the trial were generally mild to moderate and the most frequent included fatigue, dizziness, nausea and/or vomiting, paresthesia, sedation, and muscle weakness.

REYVOW can be prescribed to patients in oral doses of 50mg, 100mg, and 200mg as needed and once available.

The US FDA has given its approval for the drug.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024